A
A fibres, 397, 398
Abacavir, 136, 137, 138
Abatacept, 263, 264
Abciximab, 755, 758
Abiraterone, 212, 213
Abortifacients.
See
Prostaglandins
Absence seizure, 352, 353, 355
Absorbable gelatine, 767, 769, 770
Absorption, 15, 20–22, 891
active transport, 15, 21
drug–drug or drug–alternative therapy
interactions, 27
factors affecting, 21
first-pass effect, 21–22
passive diffusion, 16, 21
processes, 21
routes of administration, 20–21
Acarbose, 586, 588
ACE (angiotensin-converting-enzyme)
inhibitors.
See
Angiotensin-
converting enzyme (ACE)
inhibitors
Acetazolamide, 357, 361–362, 803, 805,
811
Acetic acids, 240, 246, 247
Acetylcholine, 297
receptor site, 432, 433
release, 451, 452
synthesis and storage, 451
Acetylcholinesterase, 444, 452, 487, 488
Acetylcysteine, 842, 859–860
Aciclovir, 127, 132, 133, 951, 956
Acid rebound, 896, 905
Acidification, 819, 821
Acidophilus, 962
Acromegaly, 521, 528
Actin, 642, 646
Action potential, 292, 294–295
Active immunity, 272, 273
Active transport, 15, 21
Acute myocardial infarction, 715
Adalimumab, 264, 266
Adapalene, 953
Adefovir, 127, 144, 145
A-delta fibres, 397, 398, 399
Adenosine, 698, 701, 703, 707
ADH (antiduretic hormone), 794, 798
Adiponectin, 572, 575
Adrenal cortex, 514, 536, 537
Adrenal dysfunction, 538
Adrenal glands, 537–538
adrenal crisis, 538
adrenal insufficiency, 538
controls, 537–538
Adrenal medulla, 536, 537
Adrenaline, 297, 456, 458, 676, 864, 867,
871–872
Adrenergic agonists, 455–467
adults, 456
alpha- and beta-, 456–460
adverse effects, 459
care considerations, 459–460
contraindications and cautions, 459
drug–drug interactions, 459
pharmacokinetics, 458
subdivision of receptors, 456–457
therapeutic actions and indications,
457–458
alpha-specific, 462–465, 677–678
adverse effects, 463, 677
care considerations, 464–465,
677–678
contraindications and cautions, 463,
677
drug–drug interactions, 463, 677
pharmacokinetics, 463, 677
therapeutic actions and indications,
462–463, 677
beta-specific, 465–467
adverse effects, 466
care considerations, 466–467
contraindications and cautions, 466
drug–drug interactions, 466
pharmacokinetics, 465
therapeutic actions and indications,
465
children, 456
older adults, 456
sympathetic, 676–677
toxicity, 461–462
Adrenergic blocking agents, 469–485,
658, 714
adults, 471
alpha
1
-selective blocking agents, 469,
475–477
adverse effects, 476
care considerations, 476–477
contraindications and cautions, 476
drug–drug interactions, 476
pharmacokinetics, 476
therapeutic actions and indications,
476
antianginal agents, 716, 722–723
adverse effects, 723
care considerations, 723
contraindications and cautions,
723
drug–drug interactions, 723
pharmacokinetics, 722–723
therapeutic actions and indications,
722
beta
1
-selective adrenergic blocking
agents, 469, 482–484
adverse effects, 483
care considerations, 484
contraindications and cautions, 483
drug–drug interactions, 483
pharmacokinetics, 483
therapeutic actions and indications,
482–483
children, 471
non-selective adrenergic blocking
agents, 470–473
adverse effects, 472
care considerations, 473
contraindications and cautions,
471–472
drug–drug interactions, 472
pharmacokinetics, 471
therapeutic actions and indications,
470–471
non-selective alpha-adrenergic blocking
agents, 469, 474–475
adverse effects, 474
care considerations, 474–475
contraindications and cautions, 474
drug–drug interactions, 474
pharmacokinetics, 474
therapeutic actions and indications,
474
non-selective beta-adrenergic blocking
agents, 469, 477–480
adverse effects, 478–479
care considerations, 479–480
contraindications and cautions, 478
critical thinking scenario, 480–482
drug–drug interactions, 480
pharmacokinetics, 477–478
therapeutic actions and indications,
477
older adults, 471
Adrenergic receptors, 444, 448
sites, 470
Adrenergic response, 447–449
Adrenocortical agents, 536–548
adrenal glands, 537–538
adrenal crisis, 538
adrenal insufficiency, 538
controls, 537–538
duration of effect, 539
glucocorticoids, 536, 539–545
adverse effects, 543
care considerations, 544–545
contraindications and cautions, 543
Index
